Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706549 | 1.00 | PRCP (0.40) | PRCPOPRM1OPRK1HTR2ASLC6A2 | |
| SCHEMBL19121805 | 0.83 | SLC6A2 (0.34) | PRCPOPRM1OPRK1HTR2ASLC6A2 | |
| SCHEMBL4737687 | 0.82 | PRCP (0.45) | PRCPESR1ESR2ACE | |
| SCHEMBL14985698 | 0.81 | DRD4 (0.45) | PRCPOPRM1OPRK1HTR2ASLC6A2 | |
| SCHEMBL12921565 | 0.81 | DRD4 (0.45) | PRCPOPRM1OPRK1HTR2ASLC6A2 | |
| SCHEMBL1615414 | 0.79 | OPRM1 (0.42) | PRCPOPRM1OPRK1HTR2ASLC6A2 | |
| SCHEMBL13464973 | 0.79 | OPRM1 (0.42) | PRCPOPRM1OPRK1HTR2ASLC6A2 | |
| SCHEMBL18965094 | 0.78 | HTR2A (0.38) | PRCPOPRM1OPRK1HTR2ASLC6A2 | |
| SCHEMBL19122012 | 0.77 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL20055229 | 0.75 | PRCP (0.43) | PRCPOPRM1OPRK1HTR2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2022170974-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-08-18 | — | — | WO | disclosed |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | FISH & RICHARDSON PC | 2022-04-21 | — | — | US | disclosed |
| US-20210170045-A1 | RELEASABLE ANTIBODY CONJUGATES | FISH & RICHARDSON PC | 2021-06-10 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-9060971-B2 | Combination pharmaceutical agents as inhibitors of HCV replication | ENANTA PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-8168798-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110217261-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PRCP 599/4885OPRM1 2511/4885OPRK1 2034/4885 |
| US-20110217261-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | HAVCR2, EIF2AK2, MAVS | PRCP 40/4885OPRM1 2221/4885OPRK1 2433/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | PRCP 213/4885OPRM1 4059/4885OPRK1 3954/4885 |
| US-20210170045-A1 | RELEASABLE ANTIBODY CONJUGATES | BCR, CD47, RNASE1 | PRCP 107/4885OPRM1 4281/4885OPRK1 4546/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | PRCP 898/4885OPRM1 857/4885OPRK1 636/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | PRCP 230/4885OPRM1 2601/4885OPRK1 2108/4885 |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | CASP1, CASP5, CASP2 | PRCP 213/4885OPRM1 4059/4885OPRK1 3954/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | PRCP 230/4885OPRM1 2601/4885OPRK1 2108/4885 |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | GLP1R, GIPR, IAPP | PRCP 189/4885OPRM1 2934/4885OPRK1 2388/4885 |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1B, SLC26A4 | PRCP 898/4885OPRM1 857/4885OPRK1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.